Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99% Market Closed
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Celyad Oncology SA
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celyad Oncology SA
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Celyad Oncology SA
XBRU:CYAD
Cash from Operating Activities
-€9.7m
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Cash from Operating Activities
-$21.4m
CAGR 3-Years
-1%
CAGR 5-Years
5%
CAGR 10-Years
-1%
Galapagos NV
AEX:GLPG
Cash from Operating Activities
-€327.5m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Cash from Operating Activities
-€9.8m
CAGR 3-Years
29%
CAGR 5-Years
21%
CAGR 10-Years
N/A
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
14.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.03 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Celyad Oncology SA's Cash from Operating Activities?
Cash from Operating Activities
-9.7m EUR

Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Cash from Operating Activities amounts to -9.7m EUR.

What is Celyad Oncology SA's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
20%

Over the last year, the Cash from Operating Activities growth was 52%. The average annual Cash from Operating Activities growth rates for Celyad Oncology SA have been 27% over the past three years , 20% over the past five years .

Back to Top